AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26)